Dr. van Vollenhoven has received consulting fees, speaking fees, and/or honoraria from Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Human Genome Sciences, Inc., MSD, Pfizer, Roche, and UCB (less than $10,000 each) and was an investigator in the BLISS-52 and BLISS-76 trials.
Systemic Lupus Erythematosus
Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials†
Version of Record online: 26 JUL 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 65, Issue 8, pages 2143–2153, August 2013
How to Cite
Petri, M. A., van Vollenhoven, R. F., Buyon, J., Levy, R. A., Navarra, S. V., Cervera, R., Zhong, Z. J., Freimuth, W. W. and on behalf of the BLISS-52 and BLISS-76 Study Groups (2013), Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials. Arthritis & Rheumatism, 65: 2143–2153. doi: 10.1002/art.37995
ClinicalTrials.gov identifiers: NCT00424476 and NCT00410384.
- Issue online: 26 JUL 2013
- Version of Record online: 26 JUL 2013
- Accepted manuscript online: 10 JUN 2013 08:53AM EST
- Manuscript Accepted: 24 APR 2013
- Manuscript Received: 14 NOV 2012
- Human Genome Sciences, Inc.
Additional Supporting Information may be found in the online version of this article.
|ART_37995_sm_SupplFigure1.pdf||417K||Supplementary Figure 1|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.